This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vaishampayan, U. Articles by Mitchell, M. S. Search for Related Content PubMed PubMed Citation Articles by Vaishampayan, U. Articles by Mitchell, M. S.

Active Immunotherapy of Metastatic Melanoma with Allogeneic Melanoma Lysates and Interferon

Karmanos Cancer Institute, and Division of Hematology/Oncology, Department of Medicine, Wayne State University, Detroit, Michigan 48201 [U. V., M. S. M.]; Karmanos Cancer Institute, and Department of Biostatistics, Wayne State University, Detroit, Michigan 48201 [J. A.]; and University of California, San Diego Cancer Center, La Jolla California 92093 [D. D., V. J.]

Purpose: A therapeutic lyophilized melanoma vaccine consisting of two mechanically disrupted allogeneic melanoma cell lines and the immunological adjuvant Detox-PC (Melacine) has demonstrated encouraging activity in metastatic malignant melanoma, often in regimens containing pretreatment with low-dose cyclophosphamide. In addition, IFN-2b (INTRON A; Schering-Plough Corporation, Kenilworth, NJ) has shown efficacy in melanoma refractory to Melacine. In this Phase II trial, the combination of cyclophosphamide, Melacine, and IFN was tested in metastatic malignant melanoma.

Experimental Design: Eligibility criteria included measurable disease, no prior systemic therapy for a minimum of 4 weeks, and adequate marrow, renal, and hepatic function. Cyclophosphamide was administered once at a dose of 300 mg/m² i.v. on day -3 before the first dose of Melacine. Melacine was administered at a dose of 2 x 10⁷ tumor cell equivalents per dose admixed with 0.25 ml of Detox-PC s.c. once a week on weeks 1–4 and week 6. Melacine maintenance was then given monthly from the 8th week, until progression or intolerable toxicity. IFN was started in the evening after the fourth dose of Melacine at a dose of 5,000,000 units/m² 3 times a week, and continued until progression.

Results: Forty-seven patients were enrolled, of whom 39 completed the full course and were considered evaluable. The toxicity of the regimen was minimal and consisted mainly of pain at injection sites and granulomas caused by Detox-PC, and constitutional symptoms attributable to IFN. In 39 evaluable patients, the overall objective response rate was 10.2%, but 64% of patients had stabilization of their disease for at least 16 weeks. The median time to disease progression in evaluable patients was 8 months [95% confidence interval (CI), 6–13 months]. Median survival time for all of the 47 patients enrolled was 12.5 months (95% CI, 8–15 months) with a median time to disease progression of 4 months (95% CI, 3–7 months).

Conclusion: Despite a low objective response rate, this combination holds great promise because of its tolerability and the high proportion of prolonged durations of remission or disease stabilization that it elicited.

This article has been cited by other articles:

				M. S. Mitchell In Reply J. Clin. Oncol., October 10, 2007; 25(29): 4693 - 4695. [Full Text] [PDF]

				M. S. Mitchell, J. Abrams, J. A. Thompson, M. Kashani-Sabet, R. C. DeConti, W.-J. Hwu, M. B. Atkins, E. Whitman, M. S. Ernstoff, F. G. Haluska, et al. Randomized Trial of an Allogeneic Melanoma Lysate Vaccine With Low-Dose Interferon Alfa-2b Compared With High-Dose Interferon Alfa-2b for Resected Stage III Cutaneous Melanoma J. Clin. Oncol., May 20, 2007; 25(15): 2078 - 2085. [Abstract] [Full Text] [PDF]

				S. Brode, T. Raine, P. Zaccone, and A. Cooke Cyclophosphamide-Induced Type-1 Diabetes in the NOD Mouse Is Associated with a Reduction of CD4+CD25+Foxp3+ Regulatory T Cells J. Immunol., November 15, 2006; 177(10): 6603 - 6612. [Abstract] [Full Text] [PDF]

				A. Sato, M. Ohtsuki, M. Hata, E. Kobayashi, and T. Murakami Antitumor Activity of IFN-{lambda} in Murine Tumor Models. J. Immunol., June 15, 2006; 176(12): 7686 - 7694. [Abstract] [Full Text] [PDF]

				W. E. Carson Getting Melanoma Cells to Stimulate With Frequency J. Clin. Oncol., December 10, 2005; 23(35): 8929 - 8931. [Full Text] [PDF]

				M. E. C. Lutsiak, R. T. Semnani, R. De Pascalis, S. V. S. Kashmiri, J. Schlom, and H. Sabzevari Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide Blood, April 1, 2005; 105(7): 2862 - 2868. [Abstract] [Full Text] [PDF]

				J. H. Lee, H. Torisu-Itakara, A. J. Cochran, A. Kadison, Y. Huynh, D. L. Morton, and R. Essner Quantitative Analysis of Melanoma-Induced Cytokine-Mediated Immunosuppression in Melanoma Sentinel Nodes Clin. Cancer Res., January 1, 2005; 11(1): 107 - 112. [Abstract] [Full Text] [PDF]

				S. M. Santini and F. Belardelli Advances in the Use of Dendritic Cells and New Adjuvants for the Development of Therapeutic Vaccines Stem Cells, July 1, 2003; 21(4): 495 - 505. [Abstract] [Full Text] [PDF]